Andrew is the Associate Vice President of Technical Operations at GBI. He has over 20 years of experience in both clinical and commercial manufacturing for biologics and biopharmaceuticals, including the development of large molecule therapeutics derived from recombinant therapeutic proteins and monoclonal antibodies.